Three phenyl dimer compounds, namely 3,3′-Diformyldiphenoxyethane (C₁₆H₁₄O₄) (1), 1-(4-[2-(4-Acetyl-phenoxy)-ethoxy]-phenyl)-ethanone (C₁₇H₁₆N₂O₃) (2), 1-{4-[2-(4-Acetyl-phenoxymethyl)-benzyloxy]-phenyl}-ethanone (C₂₄H₂₂O₄) (3), were obtained and fully characterized, including their crystal structure determinations. The structural properties of two compounds 4, 4^′-(ethylenedioxy)dibenzaldehyde) (C₁₆H₁₄O₄) (Tewari et al. Acta Cryst. E63:o1930, 2007) [1] (4) and 4-(2-Phenoxy-ethoxy)-benzaldehyde (C₁₅H₁₄O₃) (Valgera et al. CCDC 710835, 2016) [2] (5) are discussed with the role of the substituent in crystal packing. In vivo, anti-inflammatory activities of all compounds were studied on Wistar strain albino rats. All the compounds exhibited anti-inflammatory activity except 5. Compounds 1, 2, 4 have shown moderate-to-intermediate effects on inhibitory properties. Compound (3) with restricted rotation in the compound-like SC-558 drug was shown to possess good inhibitory properties at 180 min. In silico analysis was performed and compared with experimental in vivo results.

中文翻译：

---

柔性/限制性苯基二聚体的结构化学和抗炎活性

三种苯基二聚体化合物，即3,3'-二甲酰基二苯氧基乙烷（C ₁₆ H ₁₄ O ₄）（1），1-（4- [2-（4-乙酰基-苯氧基）-乙氧基]-苯基）-乙酮（C ₁₇ H ₁₆ N ₂ O ₃）（2），1- {4- [2-（4-乙酰基-苯氧基甲基）-苄氧基]-苯基}-乙酮（C ₂₄ H ₂₂ O ₄）（3）表征，包括其晶体结构的确定。两种化合物4、4 ^' -（亚乙基二氧基）二苯甲醛）（C ₁₆ H ₁₄ O ₄）的结构性质）（Tewari等，Acta Cryst。E63：o1930，2007）[1]（4）和4-（2-Phenoxy-ethoxy）-benzaldehyde（C ₁₅ H ₁₄ O ₃）（Valgera等，CCDC 710835，2016 ）[2]（5）讨论了取代基在晶体堆积中的作用。在体内，在Wistar白化病大鼠身上研究了所有化合物的抗炎活性。除5外，所有化合物均表现出抗炎活性。化合物1、2、4对抑制性能显示出中等到中等的影响。复合（3在化合物样SC-558药物中旋转受限）显示在180分钟时具有良好的抑制特性。进行了计算机分析，并与体内实验结果进行了比较。